Literature DB >> 26065479

CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Hollie J Pegram1, Eric L Smith1, Sarwish Rafiq1, Renier J Brentjens1,2,3.   

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma. This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic leukemia and the challenges to this therapeutic strategy. We will also discuss application of CAR T-cell therapy to chronic lymphocytic leukemia and other B-cell malignancies including a follicular lymphoma, diffuse large B-cell lymphoma, as well as acute and plasma cell malignancies.

Entities:  

Keywords:  B-cell malignancies; CAR; T cells; autologous T-cell infusion; chimeric antigen receptor; immunotherapy

Mesh：

Substances：

Year:  2015        PMID： 26065479      PMCID： PMC5238709          DOI： 10.2217/imt.15.6

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  78 in total

1.  IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia.

Authors:  D de Totero; G Reato; F Mauro; A Cignetti; S Ferrini; A Guarini; M Gobbi; C E Grossi; R Foa
Journal:  Br J Haematol       Date:  1999-03       Impact factor: 6.998

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

4.  Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Authors:  Jianhong Chu; Shun He; Youcai Deng; Jianying Zhang; Yong Peng; Tiffany Hughes; Ling Yi; Chang-Hyuk Kwon; Qi-En Wang; Steven M Devine; Xiaoming He; Xue-Feng Bai; Craig C Hofmeister; Jianhua Yu
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

5.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

8.  B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Authors:  Robert O Carpenter; Moses O Evbuomwan; Stefania Pittaluga; Jeremy J Rose; Mark Raffeld; Shicheng Yang; Ronald E Gress; Frances T Hakim; James N Kochenderfer
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

9.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

10.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.

Authors:  M Dancescu; M Rubio-Trujillo; G Biron; D Bron; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307
View more
  12 in total

Review 1.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 2.  Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Authors:  Antonia Rotolo; Anastasios Karadimitris; Marco Ruella
Journal:  Leuk Lymphoma       Date:  2017-11-22

Review 3.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

Review 4.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 5.  Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Authors:  Oladapo O Yeku; Renier J Brentjens
Journal:  Biochem Soc Trans       Date:  2016-04-15       Impact factor: 5.407

6.  Overcoming Antigen Escape with CAR T-cell Therapy.

Authors:  Hollie J Jackson; Renier J Brentjens
Journal:  Cancer Discov       Date:  2015-12       Impact factor: 39.397

Review 7.  Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Authors:  Zhenguang Wang; Yelei Guo; Weidong Han
Journal:  Protein Cell       Date:  2017-05-02       Impact factor: 14.870

Review 8.  New development in CAR-T cell therapy.

Authors:  Zhenguang Wang; Zhiqiang Wu; Yang Liu; Weidong Han
Journal:  J Hematol Oncol       Date:  2017-02-21       Impact factor: 17.388

9.  CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

Authors:  Gengwen Tian; Amy N Courtney; Bipulendu Jena; Andras Heczey; Daofeng Liu; Ekaterina Marinova; Linjie Guo; Xin Xu; Hiroki Torikai; Qianxing Mo; Gianpietro Dotti; Laurence J Cooper; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2016-05-16       Impact factor: 14.808

Review 10.  The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.

Authors:  Katayoun Rezvani; Rayne H Rouce
Journal:  Front Immunol       Date:  2015-11-17       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.